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Abstract 
Chemotherapeutic treatment of breast cancer is based on maximum tolerated dose (MTD) 
approach.1 However, advanced stage tumors are not effectively eradicated by MTD owing to suboptimal 
drug targeting, onset of therapeutic resistance and neoangiogenesis. In contrast, “metronomic” 
chemotherapy is based on frequent drug administrations at lower doses, resulting in neovascularization 
inhibition and induction of tumor dormancy.1,2 However, several limiting factors remain for LDM in order 
to displace MTD treatments in clinical practice, including 1) low drug accumulation at tumor site,2 2) 
controversial effectiveness against chemoresistance in advanced metastatic cancers, and 3) acquired 
resistance after prolonged treatment. Recent advances in nanotechnology could offer groundbreaking 
solutions to improve the effectiveness of LDM chemotherapy, by taking advantage of the unique targeting 
efficiency of engineered nanocarriers.3Here, we propose a new concept of “nanometronomic” 
chemotherapy, exploiting the H-ferritin (HFn)-mediated targeted delivery of doxorubicin (DOX)in an 
aggressive and metastatic breast cancer mouse model with DOX-inducible chemoresistance. HFn 
nanocages naturally target cancer cells4 owing to its affinity for transferrin receptor 1. HFn-DOX was 
recently demonstrated to overcome chemoresistance by actively promoting DOX nuclear translocation in 
vitro5,6 and was tested as a MTD treatment on a DOX-sensitive tumor model with encouraging results.7 We 
find that LDM administration of HFn-DOX strongly improves the antitumor potential of DOX chemotherapy 
arresting the tumor progression. Indeed, in vitro and in vivo results demonstrate that HFn nanocages 
mediate the nuclear delivery of DOX and increase DOX accumulation both in tumor tissue and in cancer 
cell nuclei, resulting in increased efficacy. Moreover, we find that HFn-DOX antitumor effect is attributable 
to multiple nanodrug actions beyond cell killing, including inhibition of tumor angiogenesis and avoidance 
of chemoresistance. Otherwise, although an even better reduction of tumor progression was achieved 
with liposomal DOX (pl-DOX) a five-fold increase in MDR-1-positive cells has been displayed, suggesting 
that liposomal DOX is not suitable in view of a protracted metronomic treatment, due to the onset of 
chemoresistance. Multiparametric assessment of heart tissues, including histology, ultrastructural 
analysis of tissue morphology, and measurement of markers of reactive oxygen species and hepatic/renal 
conditions, provided evidence that metronomic HFn-DOX allowed us to overcome cardiotoxicity contrary 
to what is observed with DOX and pl-DOX. Our results suggest that HFn-DOX has tremendous potential 
for the development of “nanometronomic” chemotherapy toward safe and tailored oncological treatments. 
1. Kareva I, et al. Cancer Lett 2015; 358: 100. 
2. Kerbel RS. Cancer Res Treat 2007; 39: 150. 
3. Cruz-Munoz W, et al. Angiogenesis 2014; 7: 661. 
4. Corsi F, Mazzucchelli S. Ther Deliv. 2016; 7: 149. 
5. Bellini M, et al.. J Controlled Rel 2014;196: 184. 
6. Zhang L, et al. Adv. Healthcare Mat. 2015; 4: 1305. 
7. Liang M, et al. Proc Natl Acad Sci USA 2014; 111: 14900. 
Citation Format: Mazzucchelli S, Fiandra L, Bellini M, Truffi M, Rizzuto MA, Sorrentino L, Longhi E, 
Nebuloni M, Prosperi D, Corsi F. H-ferritin allows nanometronomic treatment of breast cancer with 
doxorubicin preventing drug resistance and circumventing cardiotoxicity [abstract]. In: Proceedings of 
the Thirty-Ninth Annual CTRC-AACR San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San 
Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-12-17. 
 
